Nitric Oxide Production and Apoptosis Induction in T Cells through Stimulation of Mesenchymal Stem Cells with Zymosan


1 Master of Microbiology, School of Veterinary, Urmia University, Urmia, Iran

2 Associate Professor, School of Veterinary, Urmia University, Urmia, Iran

3 Assistant Professor, Artemia Research Center, Urmia University, Urmia, Iran

4 Assistant Professor, School of Veterinary, Urmia University, Urmia, Iran


Background & Aims: Mesenchymal stem cells (MSCs) are non-hematopoietic multipotant cells, which multiply through attaching to culture plates. Toll-like receptors (TLRs) are inherent immune sensors and regulators of immunomodulatory activities of MSCs. The aim of this study was to investigate the effects of zymosan on stem cell polarization into anti-inflammatory phenotypes through the production of nitric oxide and apoptosis induction in activated T cells. Methods: In this study, MSCs were isolated from mice femur and tibia bone marrow and incubated for 24 hours. Isolation of MSCs with a tendency to stick to the flask was performed during the renewing of the medium. MSCs were grown to 70 percentage of confluence in the medium, and then, they were stimulated with TLR2 agonist (5 and 25 µg/ml doses) and incubated with 5% carbon dioxide for 1 and 12 hours in 37 ºC. Supernatant medium was collected to measure nitric oxide production using Graise test. Percentage of apoptosis in activated T cells was measured using anti-CD3PE, acridin orange/propidium iodide (PI/AO) staining and flow cytometry. Results: We found that the rate of apoptosis in activated T cells increased significantly in cells incubated with a 5 µg/ml dose of zymosan for 1 hour in comparison with the control group (P < 0.05). Moreover, a significant increase was observed in nitric oxide production of cells treated with the same dose for 12 hours (P < 0.05). Conclusion: Based on these results, we can conclude that different doses, TLR agonist type, and duration of incubation impact nitric oxide production and apoptosis rate in activated T cells.


  1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8(9): 726-36.
  2. Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008; 2(4): 313-9.
  3. Hwa CH, Bae YC, Jung JS. Role of toll-like receptors on human adipose-derived stromal cells. Stem Cells 2006; 24(12): 2744-52.
  4. Frasnelli ME, Tarussio D, Chobaz-Péclat V, Busso N, So A. TLR2 modulates inflammation in zymosan-induced arthritis in mice. Arthritis Res Ther 2005; 7(2): R370-R379.
  5. Mullaly SC, Kubes P. Mast cell-expressed complement receptor, not TLR2, is the main detector of zymosan in peritonitis. Eur J Immunol 2007; 37(1): 224-34.
  6. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther 2010; 1(5): 34.
  7. Hoffman RA, Mahidhara RS, Wolf-Johnston AS, Lu L, Thomson AW, Simmons RL. Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells. Transplantation 2002; 74(6): 836-45.
  8. DelaRosa O, Lombardo E. Modulation of Adult Mesenchymal Stem Cells Activity by Toll-Like Receptors: Implications on Therapeutic Potential. Mediators of Inflammation 2010; 2010: 9.
  9. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006; 65(Suppl) 3: iii37-iii40.
  10. Nadri S, Soleimani M, Hosseni RH, Massumi M, Atashi A, Izadpanah R. An efficient method for isolation of murine bone marrow mesenchymal stem cells. Int J Dev Biol 2007; 51(8): 723-9.
  11. Camargo Bittencourt RA, Pereira HR, Felisbino SL, Murador P, Ehrhardt de Oliveira AP, Deffune E. isolation of bone marrow mesenchymal stem cells. Acta Ortop Bras 2006; 14(1): 22-4.
  12. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109(4): 1422-32.
  13. Abarbanell AM, Wang Y, Herrmann JL, Weil BR, Poynter JA, Manukyan MC, et al. Toll-like receptor 2 mediates mesenchymal stem cell-associated myocardial recovery and VEGF production following acute ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2010; 298(5): H1529-H1536.
  14. Rasmusson I, Ringden O, Sundberg B, Le BK. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 2003; 76(8): 1208-13.
  15. Delirezh N, Moazzeni SM, Shokri F, Shokrgozar MA, Atri M, Kokhaei P. Autologous dendritic cells loaded with apoptotic tumor cells induce T cell-mediated immune responses against breast cancer in vitro. Cell Immunol 2009; 257(1-2): 23-31.
  16. Ghasemi A, Hedayati M, Beiabani H, Khoshbaten A, Asgari AR. Deproteinized methods of measuring serum nitric oxide graisemetho. Pajouhesh Dar Pezeshki 2007; 31(1): 33-8. [In Persian].
  17. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26(1): 279-89.
  18. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol 2009; 217(2): 318-24.
  19. Samon JB, Champhekar A, Minter LM, Telfer JC, Miele L, Fauq A, et al. Notch1 and TGFβ1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood 2008; 112(5): 1813-21.
  20. Hocking AM, Gibran NS. Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair. Exp Cell Res 2010; 316(14): 2213-9.
  21. Ryan JM, Barry F, Mahon BP, Murphy JM. Interferon-? does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149(2): 353-63.
  22. Lombardo E, DelaRosa O, Mancheno-Corvo P, Menta R, Ramirez C, Buscher D. Toll-like receptor-mediated signaling in human adipose-derived stem cells: implications for immunogenicity and immunosuppressive potential. Tissue Eng Part A 2009; 15(7): 1579-89.
  23. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2(2): 141-50.
  24. Chen X, Armstrong MA, Li G. Mesenchymal stem cells in immunoregulation. Immunology and Cell Biology 2006; 84: 413-22.